Cover Image
市場調查報告書

Fibrocell Science, Inc.的產品平台分析

Fibrocell Science, Inc. - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 305188
出版日期 內容資訊 英文 27 Pages
訂單完成後即時交付
價格
Back to Top
Fibrocell Science, Inc.的產品平台分析 Fibrocell Science, Inc. - Product Pipeline Review - 2014
出版日期: 2014年05月30日 內容資訊: 英文 27 Pages
簡介

Fibrocell Science, Inc.ha是開發皮膚疾病用的治療藥等自體細胞治療企業。

本報告提供Fibrocell Science, Inc.上的治療藥開發平台現狀及各開發階段比較分析,提供藥物標的,作用機制,給藥途徑,各類型分子的治療藥評估,以及最新的企業新聞和發表,後期階段及中止計劃的相關資訊等。

Fibrocell Science, Inc.的基本資料

Fibrocell Science, Inc.概要

  • 主要資訊
  • 企業資料

Fibrocell Science, Inc.:R&D概要

  • 主要的治療範圍

Fibrocell Science, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Fibrocell Science, Inc.:開發中產品概況

  • 位於臨床實驗階段的開發中產品
    • 位於第二階段的產品/聯合治療模式
  • 位於初期階段的開發中產品
    • 位於前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Fibrocell Science, Inc.:藥物簡介

  • azficel-T
  • Gene Modified Autologous Fibroblast Cell Therapy
  • Autologous Fibroblast Cell Therapy for EDS-HT

Fibrocell Science, Inc.:開發平台分析

  • 各給藥途徑
  • 各類型分子

Fibrocell Science, Inc.:最近的開發平台趨勢

Fibrocell Science, Inc.:暫停中的計劃

Fibrocell Science, Inc.:企業發表

Fibrocell Science, Inc.:總公司和子公司的所在地

附錄

目錄
Product Code: GMDHC04898CDB

Global Markets Direct's, 'Fibrocell Science, Inc. - Product Pipeline Review - 2014', provides an overview of the Fibrocell Science, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Fibrocell Science, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Fibrocell Science, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Fibrocell Science, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Fibrocell Science, Inc.'s pipeline products

Reasons to buy

  • Evaluate Fibrocell Science, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Fibrocell Science, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Fibrocell Science, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Fibrocell Science, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Fibrocell Science, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Fibrocell Science, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Fibrocell Science, Inc. Snapshot
    • Fibrocell Science, Inc. Overview
    • Key Information
    • Key Facts
  • Fibrocell Science, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Fibrocell Science, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Fibrocell Science, Inc. - Pipeline Products Glance
    • Fibrocell Science, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Fibrocell Science, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
    • Discovery Products/Combination Treatment Modalities
  • Fibrocell Science, Inc. - Drug Profiles
    • azficel-T
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Modified Autologous Fibroblast Cell Therapy
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Autologous Fibroblast Cell Therapy for EDS-HT
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Fibrocell Science, Inc. - Pipeline Analysis
    • Fibrocell Science, Inc. - Pipeline Products by Route of Administration
    • Fibrocell Science, Inc. - Pipeline Products by Molecule Type
  • Fibrocell Science, Inc. - Recent Pipeline Updates
  • Fibrocell Science, Inc. - Dormant Projects
  • Fibrocell Science, Inc. - Company Statement
  • Fibrocell Science, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Fibrocell Science, Inc., Key Information
  • Fibrocell Science, Inc., Key Facts
  • Fibrocell Science, Inc. - Pipeline by Indication, 2014
  • Fibrocell Science, Inc. - Pipeline by Stage of Development, 2014
  • Fibrocell Science, Inc. - Monotherapy Products in Pipeline, 2014
  • Fibrocell Science, Inc. - Phase II, 2014
  • Fibrocell Science, Inc. - Preclinical, 2014
  • Fibrocell Science, Inc. - Discovery, 2014
  • Fibrocell Science, Inc. - Pipeline by Route of Administration, 2014
  • Fibrocell Science, Inc. - Pipeline by Molecule Type, 2014
  • Fibrocell Science, Inc. - Recent Pipeline Updates, 2014
  • Fibrocell Science, Inc. - Dormant Developmental Projects,2014
  • Fibrocell Science, Inc., Subsidiaries

List of Figures

  • Fibrocell Science, Inc. - Pipeline by Top 10 Indication, 2014
  • Fibrocell Science, Inc. - Pipeline by Stage of Development, 2014
  • Fibrocell Science, Inc. - Monotherapy Products in Pipeline, 2014
  • Fibrocell Science, Inc. - Pipeline by Top 10 Molecule Type, 2014
Back to Top